Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 02:30:00 21/01/2026 am IST			5-day change	1st Jan Change
43.78 ^USD	-0.41%		-0.68%	-0.11%

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Transcript : Exelixis, Inc., Q3 2025 Earnings Call, Nov 04, 2025

Published on 11/05/2025 at 06:05 am IST - Modified on 11/05/2025 at 07:37 am IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, ladies and gentlemen, and welcome to the Exelixis' Third Quarter 2025 Financial Results Conference Call. My name is Sherry, and I'll be your

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Exelixis, Inc.

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM
13/01	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.	CI
13/01	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.	CI
12/01	Independence, Under Review
12/01	Exelixis Provides Fiscal 2026 Revenue Guidance	MT
12/01	Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion	RE
12/01	Exelixis, Inc. Announces Preliminary Financial Results for the Year 2025 and Provides Financial Guidance for the Year 2026	CI
09/01	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
09/01	Sector Update: Health Care	MT
09/01	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
08/01	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
07/01	Enliven Therapeutics, Inc. Announces Changes in Board, Effective January 7, 2026	CI
07/01	Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial	MT
07/01	Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib	RE
07/01	Exelixis, Inc. and Natera Announce to Collaborate on STELLAR-316, Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer	CI
05/01	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
05/01	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
31/12	Exelixis, Inc.'s Equity Buyback announced on February 20, 2025, has closed with 12,271,791 shares, representing 4.5% for $500 million.	CI
11/12	Exelixis, Inc. - Special Call
25/11	Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $4,355,000, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $2,056,278, According to a Recent SEC Filing	MT
14/11	Exelixis Insider Sold Shares Worth $1,032,414, According to a Recent SEC Filing	MT
11/11	Exelixis, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-10-2025 10:30 AM